| Cancer-related molecular mechanisms research | Lifetime | 114 | CN 43 | 99.41 |
| Circular RNAs in diseases | Lifetime | 58 | CN 28 | 99.35 |
| MicroRNA in disease regulation | Lifetime | 199 | CN 65 | 99.16 |
| RNA modifications and cancer | Lifetime | 549 | CN 59 | 98.88 |
| Ferroptosis and cancer prognosis | Lifetime | 245 | CN 116 | 96.98 |
| Glioma Diagnosis and Treatment | Lifetime | 785 | CN 12 | 97.87 |
| Autophagy in Disease and Therapy | Lifetime | 450 | CN 68 | 97.06 |
| Cancer-related gene regulation | Lifetime | 740 | CN 94 | 96.65 |
| Immune cells in cancer | Lifetime | 748 | CN 96 | 96.37 |
| Cancer Mechanisms and Therapy | Lifetime | 829 | CN 157 | 92.71 |
| Vascular Malformations and Hemangiomas | Lifetime | 621 | CN 47 | 91.62 |
| Chemokine receptors and signaling | Lifetime | 867 | CN 34 | 90.47 |
| FOXO transcription factor regulation | Lifetime | 653 | CN 127 | 79.78 |
| Heterotopic Ossification and Related Conditions | Lifetime | 460 | CN 25 | 76.60 |
| Inflammation biomarkers and pathways | Lifetime | 718 | CN 118 | 73.19 |
| Cancer-related molecular mechanisms research | 2021-2025 | 47 | CN 31 | 99.55 |
| RNA modifications and cancer | 2021-2025 | 79 | CN 54 | 99.02 |
| Epigenetics and DNA Methylation | 2021-2025 | 145 | CN 64 | 96.97 |
| Ferroptosis and cancer prognosis | 2021-2025 | 113 | CN 89 | 97.92 |
| MicroRNA in disease regulation | 2021-2025 | 151 | CN 99 | 97.78 |
| RNA Research and Splicing | 2021-2025 | 148 | CN 46 | 95.79 |
| Cancer, Hypoxia, and Metabolism | 2021-2025 | 151 | CN 63 | 95.70 |
| Circular RNAs in diseases | 2021-2025 | 112 | CN 80 | 97.28 |
| Immune cells in cancer | 2021-2025 | 192 | CN 110 | 96.02 |
| Autophagy in Disease and Therapy | 2021-2025 | 111 | CN 53 | 95.53 |
| Cancer-related gene regulation | 2021-2025 | 91 | CN 59 | 94.49 |
| Vascular Malformations and Hemangiomas | 2021-2025 | 42 | CN 10 | 94.20 |
| Cancer Cells and Metastasis | 2021-2025 | 272 | CN 57 | 92.14 |
| Glioma Diagnosis and Treatment | 2021-2025 | 711 | CN 51 | 94.32 |
| Spine and Intervertebral Disc Pathology | 2021-2025 | 579 | CN 110 | 94.27 |
| Inflammasome and immune disorders | 2021-2025 | 312 | CN 157 | 90.70 |
| Traumatic Brain Injury and Neurovascular Disturbances | 2021-2025 | 747 | CN 55 | 91.31 |
| Coronary Interventions and Diagnostics | 2021-2025 | 798 | CN 64 | 91.77 |
| Spinal Fractures and Fixation Techniques | 2021-2025 | 816 | CN 114 | 89.69 |
| Vascular Malformations Diagnosis and Treatment | 2021-2025 | 505 | CN 74 | 85.36 |
| Cancer Mechanisms and Therapy | 2021-2025 | 435 | CN 174 | 82.29 |
| Cervical and Thoracic Myelopathy | 2021-2025 | 361 | CN 62 | 85.02 |
| Nerve injury and regeneration | 2021-2025 | 423 | CN 175 | 80.13 |
| Histone Deacetylase Inhibitors Research | 2021-2025 | 653 | CN 186 | 79.73 |
| Inflammatory mediators and NSAID effects | 2021-2025 | 271 | CN 53 | 78.09 |
| Parasitic infections in humans and animals | 2021-2025 | 275 | CN 64 | 78.00 |
| Scoliosis diagnosis and treatment | 2021-2025 | 804 | CN 127 | 79.92 |
| Amoebic Infections and Treatments | 2021-2025 | 194 | CN 53 | 75.22 |
| Vascular Tumors and Angiosarcomas | 2021-2025 | 311 | CN 20 | 75.59 |
| Inflammation biomarkers and pathways | 2021-2025 | 163 | CN 81 | 64.67 |
| TGF-β signaling in diseases | 2021-2025 | 164 | CN 56 | 64.12 |
| Cardiac Ischemia and Reperfusion | 2021-2025 | 718 | CN 239 | 65.14 |
| Cell death mechanisms and regulation | 2021-2025 | 545 | CN 152 | 55.70 |
| Retinopathy of Prematurity Studies | 2021-2025 | 774 | CN 118 | 53.30 |
| Heterotopic Ossification and Related Conditions | 2021-2025 | 234 | CN 64 | 49.71 |
